HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moss, R. B. Search for Related Content PubMed PubMed Citation Articles by Moss, R. B.

Administration of Aerosolized Antibiotics in Cystic Fibrosis Patients^*

^* From the Department of Pediatric Pulmonary Medicine, Stanford University Medical Center, Palo Alto, CA.

Correspondence to: Richard B. Moss, MD, FCCP, Pediatric Pulmonary Medicine, Stanford University Medical Center, 701 Welch Rd, Room 3328, Palo Alto, CA, CA 94304-5786; e-mail: rmoss{at}stanford.edu

High rates of colonization and the challenge of managing Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) have necessitated a search for safe and effective antibiotics. Currently, therapy with an aminoglycoside in combination with a ß-lactam or a quinolone antibiotic is the standard. Unfortunately, it is difficult to deliver high doses of these antibiotics via the IV route without significant systemic adverse events (AEs) (eg, ototoxicity and nephrotoxicity). Recently, a reformulation of the aminoglycoside antibiotic tobramycin has become available in a preservative-free, pH-adjusted solution for inhalation by jet nebulizer. A 96-week series of clinical studies including 520 patients, aged 6 years, with moderate-to-severe CF has evaluated the long-term safety and effectiveness of this formulation. Patients received tobramycin solution for inhalation (TSI) or placebo, which was administered in alternating cycles of 28-days-on and 28-days-off therapy, plus their usual CF care for 6 months with open-label follow-up extended to 2 years. Most AEs declined in frequency with increasing TSI exposure. Patients receiving TSI spent 25 to 33% fewer days in the hospital. Following the initiation of TSI treatment, patients experienced significant increases in FEV₁. FEV₁ values were maintained above baseline for the duration of the study series. Antibiotic susceptibility of the bacterial isolates did not predict clinical response. TSI was safe, well-tolerated, and effective for long-term treatment (96 weeks) of P aeruginosa colonization and infection in CF patients.

Key Words: aerosolized antibiotics • cystic fibrosis • Pseudomonas aeruginosa • tobramycin solution for inhalation

This article has been cited by other articles:

				P. Scheinberg, E. Shore, and on behalf of the PC-TNDS-008 Study Group A Pilot Study of the Safety and Efficacy of Tobramycin Solution for Inhalation in Patients With Severe Bronchiectasis Chest, April 1, 2005; 127(4): 1420 - 1426. [Abstract] [Full Text] [PDF]

				S P Conway Nebulized antibiotic therapy: the evidence Chronic Respiratory Disease, January 1, 2005; 2(1): 35 - 41. [Abstract] [PDF]